Molecular science to discover new therapeutic compounds
News
- Allinky's scientific founder publishes Insulin-like growth factor I sensitization rejuvenates sleep patterns in old mice
- Allinky invited to present at ASEBIO investor day
- Allinky invited to present its latest developments at Ras-Targeted Drug Discovery
- llinky showcases drug discovery programs at ASEBIO Investor Day in Madrid
- Allinky closes a successful Series A round of financing. Two new investors share our vision.
- Allinky presented its plans for the future at BioEquity 2019
- Allinky's founder Prof. Dr. Juan Jesús Pérez presents latest results on Allinky's NASH program at the World Preclinical Congress
- The Spanish Science & Technology Ministry grants two new R&D projects to Allinky
- Allinky's General Manager participates as speaker at BioSpain 2018
- Allinky showcases its latest developments on Oncology and Inflammation at BioEurope Berlin (Nov. 2017)
- Plos One publishes latest results on Allinky's allosteric modulators of MAP Kinases (+)
- Allinky accepts invitation to participate in the 2017 fourteenth annual Anglonordic Life Science Conference in London.
- Journal of Alzheimer's Disease publishes latest results on Allinky's protein-protein interaction inhibitors (+)
- The EU Eurostars Progam grants Allinky with a new project on Oncology
- Cell publishes latest results from Allinky's founder Dr. Torres Aleman (+)
- Allinky's General Manager participates as speaker in the 3rd European Neurotech & Investing & Partnering Summit in Geneva
- Nature Reviews publishes latest results from Allinky's founder Dr. Torres-Aleman: "The many faces of insulin-like signalling in the brain." (+)
Faraday 7, ES-28049 Madrid (Spain)